Skip to main content
PLOS One logoLink to PLOS One
. 2020 Dec 11;15(12):e0243617. doi: 10.1371/journal.pone.0243617

Decreasing trend of imported malaria cases but increasing influx of mixed P. falciparum and P. vivax infections in malaria-free Kuwait

Jamshaid Iqbal 1,*, Mohammad Al-Awadhi 1, Suhail Ahmad 1
Editor: Luzia Helena Carvalho2
PMCID: PMC7732060  PMID: 33306727

Abstract

Malaria still continues to be the most important parasitic disease worldwide, affecting 228 million people and causing 405,000 deaths each year. In this retrospective study during 2013 to 2018, we documented the incidence of imported malaria infection and evaluated the impact of malaria preventive measures in Kuwait, a non-endemic country. The epidemiologic and demographic data of all malaria cases was collected from the Infectious Diseases Hospital, Kuwait where all suspected cases of malaria are referred for confirmation and therapeutic intervention. The diagnosis of malaria infection was done by microscopy of Giemsa stained blood films. Selected samples were retested with BinaxNOW® Malaria rapid test and molecular assay to reconfirm the Plasmodium spp. or mixed infection. Overall, 1913 (25.9%) malaria cases were detected, 81.5% of which were among male subjects. Male subjects had higher incidence of P. vivax malaria (113; 91.1%) and mixed infection with P. falciparum and P. vivax (1245; 90.0%) compared to females who had higher rate of P. falciparum infection (52.4%). An overwhelming majority of malaria cases (1895; 99.1%) were detected among expatriates from malaria-endemic countries; India (1012; 52.9%), Pakistan (390; 20.4%), Afghanistan (94; 4.9%) and African countries (313; 16.3%). Only 18 cases involved Kuwaiti nationals, all with a history of travel to African countries. The majority of malaria cases were detected during the summer and fall months (May-October). Our data showed that the incidence rate of imported malaria cases was stable during 2013 to 2018, however, the incidence of total malaria cases showed a declining trend over the years. This study confirms that the preventive program has been successful in reducing the incidence of imported malaria infections in Kuwait. The most striking finding of this study was high incidence of mixed infection with P. falciparum and P. vivax, with almost all (97%) cases among workers from India.

Introduction

Despite widespread control and elimination efforts, malaria still continues to be the most important parasitic disease worldwide, affecting 228 million people and causing 405,000 deaths in 2018, mostly in tropical and sub-tropical countries [1]. Although the major burden of malaria is in Africa, Asian countries suffer as well. Approximately 85% of malaria deaths occurred in 20 sub-Saharan African countries and India [1]. It is now well documented that population movements play an important role in the spread and introduction of malaria in nonendemic areas [25]. Over 40 million individuals from developed countries visit malaria-endemic countries each year, resulting in nearly 20,000 malaria cases in returning travelers in industrialized countries annually [4, 5]. Similarly, over 35 million people from malaria-endemic countries visit the developed world. Furthermore, military conflicts, civil unrest and ecologic changes have also contributed to global resurgence of malaria as large number of unprotected and nonimmune refugees have moved into malaria-endemic areas [6].

There have been no reports of local malaria transmission in most of the Middle eastern countries including Kuwait, except few reports from Saudi Arabia and Oman [712]. However, imported malaria was a major public health problem during the 1990s in Kuwait as >700 cases were detected annually among migrant workers from malaria-endemic countries [12]. The current population of 4.7 million inhabitants in the State of Kuwait comprises 70% expatriate workers and their family members originating mainly from South Asian and African countries [13]. Although total number of malaria cases in Kuwait initially decreased over the years as a result of malaria control program initiated in 1985 [12], no data are available to confirm this decreasing trend in recent years. This retrospective epidemiologic study was carried out to reevaluate the impact of ongoing preventive measures on the current status of imported malaria cases during 2013 to 2018 in Kuwait.

Materials and methods

Extraction, categorization and entry of epidemiological data

Malaria infection is a notifiable disease in Kuwait. Though all migrant workers from malaria endemic countries entering Kuwait for the 1st time are required to carry a recent malaria-free certification issued by the designated Diagnostic Laboratories in their home countries, however, they are also screened for malaria infection at the Ports and Borders Health Centers in Kuwait. Kuwait is a small country consisting of six administrative governorates. All malaria positive cases are then referred to the Malaria Reference Laboratory, Infectious Diseases Hospital (MRL, IDH), Kuwait for treatment and follow up. In addition, any resident in Kuwait suspected of malaria infection is referred to the MLR, IDH for confirmation and therapeutic management. For all cases, information on civil identification number, age, gender, nationality, referring hospital, date of sample collection, major clinical symptoms, recent travel history and test results are recorded in the MLR, IDH registry logbooks.

The epidemiologic and demographic data of all cases was collected from the registry logbooks of MRL, IDH during the period January 2013 to December 2018.

Diagnosis of malaria

The diagnosis of Plasmodium spp. infection was performed on the venous whole blood collected in EDTA collection tubes. A thick and thin blood film were prepared from each specimen, fixed in ethanol and stained with Giemsa solution for 30 min to determine the parasite stage by light microscopy. Serological testing was performed on blood samples to confirm Plasmodium spp. by using the rapid BinaxNOW® Malaria rapid diagnostic test (Alere, Cologne, Germany) according to manufacturer’s instructions and as described previously [14]. Briefly, 15 μl of whole blood was added to the designated purple area of nitrocellulose test strip labeled with anti-HRP-2 and aldolase monoclonal antibodies. Subsequently, Reagent A (tris buffer + Triton® X-100 + sodium azide) was used to process the test and the results were read after 15 min from the result window. A positive test result showed both the control line and test line(s), while a negative test result produced only the control line. Absence of control line indicated an invalid result.

Detection of Plasmodium species by real-time polymerase chain reaction (PCR)

Specimens not processed for PCR within 2 days were stored at 2–8°C. A genus-specific primer set corresponding to the 18S rRNA was used to amplify the target sequence. Real-time PCR detection of Plasmodium species was performed blinded to the microscopy and malaria rapid test results. All PCRs were performed using the LightCycler-FastStart DNA Master Hybridization Probes kit (Roche Applied Science) as described earlier [15]. An internal control was used to monitor the DNA isolation procedure and to check for possible PCR inhibition. Briefly, each reaction had a final concentration of 4 μM MgCl2, 0.5 μM primer PF1, 1.0 μM primer PF2, 0.2 μM probe PF3, and 0.4 μM probe PF4. The amplification and detection was carried out as described earlier with minor modifications to the thermal profile [15]. Amplification of different Plasmodium species yielded products with different melting temperature curves and mixed infections showed double curve with appropriate species temperatures. The limit of detection (LOD) of the assay was determined at 1–5 parasites/μl of blood (≤ 0.0001% of infected red blood cells).

Statistical analysis

Descriptive statistical analysis was performed, and Pearson’s Chi-square was used to test association of infection with patient’s sociodemographic profile. Student’s t-test was used to measure the difference in age between infected and non-infected patients. A P-value less than 0.05 was considered as statistically significant.

Ethical clearance

This study was approved by the Health Sciences Center Ethical Committee, Kuwait University, and the Ethical Committee for the Protection of Human Subjects in Research, Ministry of Health, Kuwait, under reference no. 187/2014 which is in agreement with the code of ethics of the World Medical Association. Personal details about individual participants were not disclosed and the data were analyzed anonymously.

Results

Between January 2013 and December 2018, a total of 7386 subjects were referred to the Infectious Diseases Hospital for malaria investigation. Overall, 1913 (25.9%) patients tested positive for malaria. Most malaria cases were detected among male patients (n = 1560; 81.5%) (Table 1). However, the number of female subjects infected with P. falciparum was significantly higher (n = 189; 52.4%) in comparison with male patients (n = 172; 47.6%), whereas male subjects had a significantly higher incidence of P. vivax malaria (n = 113; 91.1%) and mixed infection with P. falciparum and P. vivax (n = 1245; 90.0%) in comparison with female subjects (n = 11; 8.9% and n = 138; 10.0%, respectively) (P <0.001) (Table 1).

Table 1. Distribution of malaria cases by causative Plasmodium spp., gender and mean age in Kuwait (2013–2018).

Plasmodium spp. n, (%) Mean age in years P-value
(95% Confidence Interval)
All Plasmodium spp. 1913 (100.0%) 34.1 (33.6, 34.6)
 Male 1560 (81.5%) 34.9 (34.4, 35.4) <0.001
 Female 353 (18.5%) 30.5 (29.5, 31.5)b
P. falciparum + P. vivax 1383 (72.3%) 35.2 (34.7, 35.7)
 Male 1245 (90.0%) a 35.2 (34.6, 35.8) <0.001
 Female 138 (10.0%) 35.1 (33.2, 37.0)
P. falciparum 361 (18.9%) 30.2 (29.2, 31.2)
 Male 172 (47.6%) 33.6 (31.9, 35.3) <0.001
 Female a 189 (52.4%)a 27.1 (26.2, 28.0) b
P. vivax 124 (6.5%) 35.4 (33.7, 37.1)
 Male 113 (91.1%) a 35.6 (33.9, 37.3) <0.001
 Female 11 (8.9%) 33.0 (27.3, 38.7)
P. falciparum + P. ovale 25 (1.3%) 29.4 (25.8, 33.0)
 Male 20 (80.0%) 29.2 (25.0, 33.4) N/A
 Female 5 (20.0%) 30.4 (20.8, 40.0)
P. falciparum + P. malariae 12 (0.6%) 27.9 (22.7, 33.1)
 Male 5 (41.7%) 28.0 (15.2, 40.8) N/A
 Female 7 (58.3%) 27.9 (21.2, 34.6)
P. ovale 8 (0.4%) 30.6 (16.7, 44.5)
 Male 5 (62.5%) 29.0 (7.6, 50.4) N/A
 Female 3 (37.5%) 33.3 (N/A)

a Indicates points of significance based on gender.

b Indicates points of significance based on mean age (years).

The age of subjects with malaria ranged from 1 to 73 years with a mean of 34.1 years (95% CI: 33.6, 34.5). The mean age of female subjects [30.5 years (95% CI: 29.6, 31.4)] was significantly lower than that of male subjects [34.9 years (95% CI: 34.4, 35.4)] (P <0.001) (Table 1). In particular, the mean age of females [27.1 years (95% CI: 26.2, 28.0)] infected with P. falciparum was significantly lower in comparison with that of P. falciparum-infected male patients [33.6 years (95% CI: 31.9, 35.3)] (P <0.001). Both the total number of malaria and P. falciparum infections among the male and female cases showed a single peak of age distribution on histograms, 22–33 vs 20-28-year age group for total malaria cases & 21–34 vs 23-26-year age group for P. falciparum cases respectively (S1 Fig in S1 File).

Only 18 (0.9%) positive cases were among Kuwaiti nationals returning from overseas visit while the remaining cases had come to Kuwait from several other countries in the descending order as follows: India (1012; 52.9%), Pakistan (390; 20.4%), Afghanistan (94; 4.9%), Cameroon (54; 2.8%), Sudan (48; 2.5%), Ghana (46; 2.4%), other African countries (165; 8.6%) and other countries (86; 4.4%). Thus a large majority (1507; 78.8%) were non-Arab Asians mainly originating from India, Pakistan and Afghanistan, while malaria cases originating from non-Arab African countries (303; 15.8%) and Arab countries (82; 4.3%) formed minority group (Fig 1).

Fig 1. A pie chart showing the share (n, %) of reported malaria cases among the ethnic groups in Kuwait (2013–2018).

Fig 1

Surprisingly, the majority (1420 of 1913, 74.2%) of malaria cases had a mixed infection with both P. falciparum and P. vivax (1383; 72.3%) or P. falciparum and P. ovale (25; 1.3%) or P. falciparum and P. malariae (12; 0.6%) while other cases were caused by P. falciparum alone (361; 18.9%) or P. vivax (124; 6.5%) alone (Fig 2). Almost all malaria cases which had a mixed infection with P. falciparum and P. vivax (1303; 97.0%) originated from India (878; 67.4%), Pakistan (341; 26.2%) and Afghanistan (84; 6.4%).

Fig 2. A pie chart showing the share (n, %) of reported malaria cases infected with different species of malaria in Kuwait (2013–2018), mixed infection with P. falciparum and P. vivax constituting the major infection type.

Fig 2

The annual number of reported malaria cases remained stable between 262–312 cases during 2013–2015 but showed a significant increase from 2015 to 2017 (409 cases) before declining again in 2018 (Fig 3). The annual number of cases which had mixed infection with P. falciparum and P. vivax showed a declining trend during 2013 to 2015 but showed an increasing trend during 2015 to 2017 before declining again in 2018. On the other hand, the data showed an increasing trend in the number of P. falciparum infections alone and a decreasing trend in the number of P. vivax cases alone from 2013 to 2018 (Fig 3). The number of malaria cases detected in Kuwait were significantly higher during the summer and fall months with maximum number of cases detected during the summer months of July (252; 13.2%), August (273; 14.3%) and September (265, 13.9%) (S2 Fig in S1 File).

Fig 3. A line graph showing the annual number of reported malaria cases by Plasmodium spp. with significantly higher numbers of P. falciparum and P. vivax mixed infection in Kuwait (2013–2018) (P <0.001).

Fig 3

Discussion

The ever increasing travel for business and/or leisure and migratory movements for employment or displacement/forced movement of refugees within and across national borders due to geopolitical conflicts have changed epidemiological characteristics of imported malaria in many non-malaria-endemic countries [46, 16]. The relative risk of malaria infection in travelers visiting different countries can be roughly estimated by using the surveillance data and the disease characteristics in different areas. Approximately, 3.3 million of ~4.7 million inhabitants in 2019 in Kuwait were expatriate workers from many malaria-endemic countries. A systematic survey of imported malaria cases in Kuwait between January 2013 and December 2018 was conducted and the data were compared with a previous survey conducted nearly a decade ago.

Our data showed that 1913 malaria cases were detected among 7386 suspected cases in Kuwait with yearly low of 262 cases in 2014 to a high of 409 cases in 2017. This rate is considerably lower than the data reported in an earlier study conducted during 1985–2000 showing an infection rate of >1200 cases/year of imported malaria cases [12]. Since the total population of Kuwait has changed drastically in recent years due to influx of large number of expatriates mainly from malaria-endemic countries, it was of interest to determine the incidence rate of malaria during this study period. The data showed that the incidence rate was stable during 2013 to 2018 (Fig 4). When the data were combined with data from our previous study [12], it became apparent that the incidence of total malaria cases have shown a declining trend in the number of imported malaria cases over the years, especially after 1994 (Fig 4). This is likely attributed to the well-organized malaria control program initiated by the Preventive Department of the Ministry of Health in 1996, comprising pre-screening of migrant workers from malaria-endemic countries in their home countries before their travel to Kuwait, further screening of all expatriates upon entry into Kuwait, spraying of insecticides in agricultural lands and mandatory reporting of positive malaria cases. On the contrary, number of malaria cases reported among returning resident expatriates increased after visiting their home country, likely due to their semi-immune status. Similar observations have also been made in other adjoining GCC countries including Bahrain [17], Qatar [18, 19], and Saudi Arabia [2022].

Fig 4. A line graph showing a comparison of reported malaria incidence rates in Kuwait (per 100,000 persons) from a previous study (1992–2000) [12] and this study (2013–2018).

Fig 4

The clinical and epidemiological features recorded in our study showed that an overwhelming majority of malaria cases (1895; 99.1%) were detected among expatriates (imported malaria cases), originating from malaria-endemic countries, particularly from India, Pakistan and Afghanistan, as expected. Only 18 cases involved Kuwaiti nationals, all with a history of travel to malaria-endemic African countries. The highest number of malaria cases (1012; 52.9%) were detected among Indians which also form the biggest single ethnic group among expatriate residents in Kuwait [13]. Similar data have also been reported from other Arabian Gulf countries, such as Qatar, Bahrain, United Arab Emirates and Saudi Arabia which also have large expatriate population, particularly from the Indian sub-continent [1719, 23, 24].

The majority of malaria cases were detected among male subjects and during the summer and fall months (May-October), which coincides with the rainy season/peak malaria infection period in the home countries of expatriate workers who either came or returned to Kuwait after summer holidays. Males also comprised >90% of all imported malaria cases in Qatar [19], UAE [23] and Saudi Arabia [24]. Furthermore, similar seasonal trend was also reported from other GCC countries with most imported cases detected during the months of August-September [18, 23, 25]. The malaria cases among returning expatriate subjects could be the result of declined immunity due to their prolonged stay in non-endemic Kuwait which probably resulted in increased susceptibility to malaria infection during their subsequent visits to home countries. Although there is no sensitive biomarker to measure the anti-parasite immunity in the residents or travelers, current evidence indicates variable responses to malaria infection depending on the anti-parasite immune status of the host [4].

A striking observation of our study was the detection of mixed P. falciparum and P. vivax infections in the majority (1383; 72.3%) of malaria cases followed by P. falciparum monoinfection in 361 (18.9%) cases. Nearly all (97%) of the mixed infection cases were found among subjects from India. The diagnosis was made by using a highly sensitive serological test [14]. Misdiagnosis was ruled out by retesting several selected samples by a molecular (PCR) assay [15]. In an earlier survey carried out during 1990–2000 in Kuwait, P. vivax was the dominant Plasmodium spp. detected among the migrant workers, including expatriates from India [12]. It is pertinent to mention here that P. falciparum which had dominated India’s malaria cases previously, is now showing a decreasing trend over the last few years, 65.4% in 2017 to 46.4% in 2019 while majority of malaria cases are now caused by P. vivax [26]. Consistent with our findings, several recent studies from India which had employed molecular (PCR) methods for detection of malaria cases had also reported mixed P. falciparum/P. vivax infections in 11% to 45% of patient samples [27, 28]. Some studies have also concluded that since field diagnosis of malaria at the primary health care level in India is mostly performed by microscopy which has low sensitivity/accuracy in diagnosing multiple species malaria, cases of mixed species infection are usually missed [27, 2931]. This is also evident from the fact that ~17% of mixed infections were initially identified as monoinfections due to P. falciparum in one study from India [29]. A recently developed field-applicable, rapid, ultrasensitive diagnostic assay that specifically detects DNA sequences from all Plasmodium species in symptomatic and asymptomatic malaria is expected to detect low level and mixed-Plasmodium spp. infections more efficiently [32]. The new malaria diagnostic method combines an optimized 10-minute rapid sample preparation protocol with the CRISPR-based SHERLOCK system to enable highly specific and sensitive Plasmodium detection in another 60 minutes in simple reporter devices. It is published in PNAS.

The detection of mixed P. falciparum and P. vivax infections in 72.3% of malaria cases in Kuwait is the highest reported so far from among the GCC countries. The majority of imported malaria cases in Qatar and United Arab Emirates are caused by P. vivax followed by P. falciparum [19, 23], and mixed P. falciparum and P. vivax infections are less frequent, occurring only in 2% of the cases [19, 33]. On the contrary, P. falciparum malaria is more common in locally acquired malaria cases while an increasing proportion of imported cases were caused by P. vivax in Saudi Arabia [7, 20, 24]. Mixed P. falciparum and P. vivax infections occurred in only ~7% of malaria cases in one study [8], while in another study, nearly 2% of PCR-confirmed malaria cases (n = 369) were due to mixed infections that were missed by microscopic analysis alone [34].

All mixed infections with P. falciparum + P. vivax were treated with artemether+lumefantrine, given twice a day for 3 days. This treatment was followed by treatment with the standard dose of primaquine (0.25 mg/kg/day) for 28 days to treat hypnozoite stage of the P. vivax. Though the WHO has also recommended a higher dosage of primaquine (0.5 mg/kg/day) for 14 days, however, we used the standard dose for primaquine to minimize the side effect of hemolysis especially in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency. However, up to 20% of the mixed Plasmodium cases showed relapse of mixed Plasmodium infection 3–4 months after therapeutic/radical anti-malarial treatment with no travel history to the Indian sub-continent. A number of studies have reported in mixed malaria, an increase in relapse rates by P. vivax following treatment of P. falciparum [35]. Though, the most common cause of P. vivax relapse is poor adherence to treatment or inappropriate dose, however, failure in treatment due to impairment in CYP2D6 enzyme is also being investigated [36].

Studies are urgently needed to investigate the molecular basis of resistance of mixed Plasmodium infections in Kuwait and correlation with disease severity and outcome. Recently, a number of reports have documented an influx of diverse, drug resistant malaria cases in the neighboring countries of Qatar and Saudi Arabia [10, 33, 37]. Moreover, the ICMR-National Institute of Malaria Research (ICMR-NIMR) in India has recently reported drug resistant strains of P. falciparum, mainly from East and Northeast of India [17, 38].

Although autochthonous malaria cases have been reported from two GCC countries (Oman and Saudi Arabia) [79, 21], no autochthonous malaria cases have been detected in Kuwait so far. However, certain risk factors have emerged recently in and around the country which may endanger the present situation. These factors are: i) A change in the present ecological and meterological conditions due to an enthusiastic drive for making Kuwait green and extending plantations throughout country. Presently the larval density levels of A. stephensi and A. pulcherrimus are well below the threshold for transmission due to arid conditions. ii) the extensive use of water for agricultural irrigation and domestic purposes, iii) recent reports of imported drug resistant malaria cases in the neighboring country, Qatar [33]. A significant change in the drug sensitivity pattern of P. falciparum isolates from these countries and this report of imported mixed Plasmodium infections from India will have an important impact on the future therapeutic, as well as prophylactic policies for P. falciparum infection in Kuwait.

In summary, this study confirms that the proactive preventive program has been successful in reducing the incidence of imported malaria infections in Kuwait and has now shifted the burden of malaria cases towards returning expatriate residents, who are now regarded as the high-risk group for acquisition of travel-associated malaria. This group is now being targeted for prevention strategies such as education and information on various preventive measures before their travel to endemic countries. The most striking finding of this study was prevalence of mixed infections with both P. falciparum and P. vivax (72.3%) with almost all (97%) cases involving migrant workers from India. This observation needs to be followed up with more detailed comparative analysis of various diagnostic tests at the Malaria Center, Infectious Disease Hospital, Kuwait and recording of comprehensive demographic data, especially the location/area of residence of the incoming expatriate population to follow up the recent update of malaria incidence infection of that location. In addition, up to 20% of the mixed Plasmodium cases showed recrudescence of mixed Plasmodium infection 3–4 months after therapeutic and radical anti-malarial treatment. A significant change in the drug sensitivity pattern of P. falciparum isolates from these countries and the finding of imported mixed Plasmodium infections from India will have an important impact on the future therapeutic, as well as prophylactic policies for P. falciparum infections in Kuwait.

Supporting information

S1 File

(DOCX)

Acknowledgments

We would like to thank Dr. Mamoun Al-Qaseer and Dr. Ali Sher for sharing their epidemiological data on malaria cases at the Malaria Reference Laboratory, Infection Diseases Hospital, Ministry of Health, Kuwait.

Data Availability

All relevant data are within the manuscript and its Supporting information files.

Funding Statement

The financial support for this study was provided by the Research Sector and College of Graduate Studies, Kuwait University, Kuwait under the Research Project YM 06/14. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1.World Health Organization. Malaria, 2020. https://www.who.int/news-room/fact-sheets/detail/malaria (14 January 2020, date last accessed)
  • 2.Ahmad S, Mokaddas E, Al-Mutairi NM. Prevalence of tuberculosis and multidrug resistant tuberculosis in the Middle East Region. Expert Rev Anti Infect Ther. 2018; 16: 709–21. 10.1080/14787210.2018.1519393 [DOI] [PubMed] [Google Scholar]
  • 3.Al-Awadhi M, Iqbal J, Ahmad S. Cysticercosis, a potential public health concern in Kuwait: a new diagnostic method to screen Taenia solium taeniasis carriers in the expatriate population. Med Princ Pract. 2020; 29: 347–353. 10.1159/000504625 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Mischlinger J, Rönnberg C, Álvarez-Martínez MJ et al. Imported malaria in countries where malaria is not endemic: A comparison of semi-immune and nonimmune travelers. Clin Microbiol Rev. 2020; 33(2): e00104–19. 10.1128/CMR.00104-19 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Norman FF, Comeche B, Chamorro S, Pérez-Molina J-A, López-Vélez R. Update on the major imported protozoan infections in travelers and migrants. Future Microbiol. 2020; 15: 213–25. 10.2217/fmb-2019-0212 [DOI] [PubMed] [Google Scholar]
  • 6.Guerra CA, Kang SY, Citron DT, Dianna E. B. Hergott, Megan Perry, Jordan Smith et al. Human mobility patterns and malaria importation on Bioko Island. Nat Commun. 2019; 10(1): 2332 10.1038/s41467-019-10339-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Alshahrani AM, Abdelgader TM, Mohya M, Jubran S, Abdoon AMO, Daffalla AA, et al. Risk Associated with Malaria Infection in Tihama Qahtan, Aseer Region, Kingdom of Saudi Arabia: 2006–2007. Malar Control Elimin. 2019. June 25; 5(2): 144 10.4172/2470-6965/1000144 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Hawash Y, Ismail K, Alsharif K, Alsanie W. Malaria Prevalence in a Low Transmission Area, Jazan District of Southwestern Saudi Arabia. Korean J Parasitol. 2019. June; 57(3): 233–242. 10.3347/kjp.2019.57.3.233 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Simon B, Sow F, Al Mukhaini SK, Al-Abri S, Ali OAM, Guillaume Bonnot G, et al. An outbreak of locally acquired Plasmodium vivax malaria among migrant workers in Oman. Parasite (Paris, France). 2017; 24: 25 10.1051/parasite/2017028 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Soliman RH, Garcia-Aranda P, Elzagawy SM, Boshra El-Sayed Hussein BE, Mayah WW, Ramirez AM et al. Imported and autochthonous malaria in West Saudi Arabia: Results from a reference hospital. Malaria Journal 2018; 17(1): 286 10.1186/s12936-018-2438-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Snow RW, Amratia P, Zamani G, Mundia CW, Noor AM, Memish ZA et al. The malaria transition on the Arabian Peninsula: progress toward a malaria-free region between 1960–2010. Adv Parasitol. 2013; 82: 205–2051. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Iqbal J, Al-Ali F, Faiza Al-Ali F, Sher A, Hira PR. Imported malaria in Kuwait (1985–2000). J Travel Med. 2003; 10(6): 324–29. 10.2310/7060.2003.9291 [DOI] [PubMed] [Google Scholar]
  • 13.The Public Authority for Civil Information. 2019 Statistical Reports. https://www.csb.gov.kw/Pages/Statistics_en?ID=6&ParentCatID=1 (14 August 2020, date last accessed).
  • 14.Ota-Sullivan K, Blecker-Shelly DL. Use of the rapid BinaxNOW malaria test in a 24-hour laboratory associated with accurate detection and decreased malaria testing turnaround times in a pediatric setting where malaria is not endemic. J Clin Microbiol. 2013; 51(5): 1567–69. 10.1128/JCM.00293-13 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Swan H, Sloan L, Muyombwe A, Chavalitshewinkoon-Petmitr P, Krudsood S, Leowattana W, et al. Evaluation of a real-time polymerase chain reaction assay for the diagnosis of malaria in patients from Thailand. Am J Trop Med Hyg. 2005; 73(5): 850–854. [PubMed] [Google Scholar]
  • 16.Loutan L. Malaria: still a threat to travellers. Inter J Antimicro Agents 2003; 21(2): 158–63. [DOI] [PubMed] [Google Scholar]
  • 17.Ismaeel AY, Senok A., Jassim Al-Khaja KA, Botta GA. Status of malaria in the Kingdom of Bahrain: a 10-year review. J Travel Med. 2004; 11(2): 97–101. 10.2310/7060.2004.17059 [DOI] [PubMed] [Google Scholar]
  • 18.Al-Kuwari MG. Epidemiology of imported malaria in Qatar. J Travel Med. 2009; 16(2): 119–122. 10.1111/j.1708-8305.2008.00285.x [DOI] [PubMed] [Google Scholar]
  • 19.Farag E, Bansal D, Chehab MAH, Al-Dahshan A, Bala M, Ganesan N, et al. Epidemiology of Malaria in the State of Qatar, 2008–2015. Mediterr J Hematol Infect Dis. 2018. September 1; 10(1): e2018050 10.4084/MJHID.2018.050 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Coleman M, Al-Zahrani MH, Coleman M, Hemingway J, Omar A, Stanton MC, et al. A country on the verge of malaria elimination-the Kingdom of Saudi Arabia. PLoS One 2014. September 24; 9(9): e105980 10.1371/journal.pone.0105980 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.El Hassan IM, Sahly A, Alzahrani MH, Alhakeem RF, Alhelal M, Alhogail A, et al. Progress toward malaria elimination in Jazan Province, Kingdom of Saudi Arabia: 2000–2014. Malar J. 2015. November 9; 14: 444 10.1186/s12936-015-0858-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Murray CJ, Ortblad KF, Guinovart, Lim SS, Wolock TM, Roberts DA et al. Global, regional, and national incidence and mortality for HIV, tuberculosis, and malaria during 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2014; 384: 1005–1070. 10.1016/S0140-6736(14)60844-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Nilles EJ, Alosert M, Mohtasham MA, Saif M, Sulaiman L, Seliem RM, et al. Epidemiological and clinical characteristics of imported malaria in the United Arab Emirates. J Travel Med. 2014. May-Jun; 21(3): 201–206. 10.1111/jtm.12110 [DOI] [PubMed] [Google Scholar]
  • 24.Alshahrani AM, Abdelgader TM, Saeed I, AbdulRhman Al-Akhshami, Al-Ghamdi Mohamed, Al-Zahrani Mohammed H. et al. The changing malaria landscape in Aseer region, Kingdom of Saudi Arabia: 2000–2015. Malar J 2016. November 8; 15(1): 538 10.1186/s12936-016-1581-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Bashwari LA, Mandil AM, Bahnassy AA, Al-Shamsi MA, Bukhari HA. Epidemiological profile of malaria in a university hospital in the eastern region of Saudi Arabia. Saudi Med J. 2001; 22(2): 133–138. [PubMed] [Google Scholar]
  • 26.National Vector Borne Disease Control Program/Ministry of Health and Family Welfare, Government of India. Malaria Report 2020. https://nvbdcp.gov.in/index1.php?lang=1&level=1&sublinkid=5784&lid=3689 (20 August 2020, date last accessed).
  • 27.Dayanand KK, Kishore P, Chandrashekar V, Kiran K, Achur RN, Ghosh SK, et al. Malaria severity in Mangaluru City in the southwestern coastal region of India. Am J Trop Med Hyg. 2019; 100(2): 275–279. 10.4269/ajtmh.18-0005 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Gupta B, Gupta P, Sharma A, Singh V, Dash AP, Das A. High proportion of mixed-species Plasmodium infections in India revealed by PCR diagnostic assay. Trop Med Int Health 2010; 15: 819–824. 10.1111/j.1365-3156.2010.02549.x [DOI] [PubMed] [Google Scholar]
  • 29.Haanshuus CG, Chandy S, Manoharan A, Vivek R, Mathai D, Xena D. A high malaria prevalence identified by PCR among patients with acute undifferentiated fever in India. PLoS One. 2016;11(7): e0158816 10.1371/journal.pone.0158816 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Punnath K, Dayanand KK, Chandrashekar VN, Achur RN, Kakkilaya SB, Ghosh SK, et al. Clinical features and haematological parameters among malaria patients in Mangaluru City area in the southwestern coastal region of India. Parasitol Res 2020; 119(3): 1043–1056. 10.1007/s00436-019-06540-2 [DOI] [PubMed] [Google Scholar]
  • 31.Siwal N, Singh US, Dash M, Kar S, Rani S, Rawal C, et al. Malaria diagnosis by PCR revealed differential distribution of mono and mixed species infections by Plasmodium falciparum and P. vivax in India. PLoS One. 2018; 13(3): e0193046 eCollection 2018 10.1371/journal.pone.0193046 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Lee RA, Puig HD, Nguyen PQ, Angenent-Mari NM, Donghia NM, McGee JP, et al. Ultrasensitive CRISPR-based diagnostic for field-applicable detection of Plasmodium species in symptomatic and asymptomatic malaria. Proceed of Natl Acad of sci, USA, September 21, 2020 10.1073/pnas.2010196117 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Al-Rumhi A, Al-Hashami Z, Al-Hamidhi S, Gadalla A, Naeem R, Ranford-Cartwright L, et al. Influx of diverse, drug resistant and transmissible Plasmodium falciparum into a malaria-free setting in Qatar. BMC Infect Dis. 2020;20(1): 413 10.1186/s12879-020-05111-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Bin Dajem SM. Molecular investigation of mixed malaria infections in southwest Saudi Arabia. Saudi Med J. 2015. February; 36(2): 248–251. 10.15537/smj.2015.2.10874 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Ashley EA, Phyo AP, Carrara VI, Tun KM, Nosten F, Smithuis F, et al. Plasmodium vivax relapse rates following Plasmodium falciparum malaria reflect previous transmission intensity. J Infect Dis. 2019; 220 (1), 100–104, 10.1093/infdis/jiz052 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Ramírez AM, González CL, Maniega TS, Liarte AG, Garcia DD, Suarez ML et al. Several Plasmodium vivax relapses after correct primaquine treatment in a patient with impaired cytochrome P450 2D6 function. 2020; Malar J. 19, 259 10.1186/s12936-020-03326-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Acharya A, Bansal D, Bharti PK, Fahmi Y Khan FY, Salem Abusalah S, Ashraf Elmalik A. et al. Molecular surveillance of chloroquine drug resistance markers (Pfcrt and Pfmdr1) among imported Plasmodium falciparum malaria in Qatar. Path Glob Health. 2018; 112(2): 57–62. 10.1080/20477724.2017.1399234 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Guerin PJ, Dhorda M, Ganguly NK, Sibley CH. Malaria control in India: A national perspective in a regional and global fight to eliminate malaria. J Vector Borne Dis. 2019; 56(1): 41–45. 10.4103/0972-9062.257773 [DOI] [PubMed] [Google Scholar]

Decision Letter 0

Luzia Helena Carvalho

Transfer Alert

This paper was transferred from another journal. As a result, its full editorial history (including decision letters, peer reviews and author responses) may not be present.

28 Oct 2020

PONE-D-20-30612

Decreasing trend of imported malaria cases but increasing influx of mixed P. falciparum and P. vivax infections in malaria-free Kuwait

PLOS ONE

Dear Dr. Iqbal,

Thank you for submitting your manuscript for review to PLoS ONE. After careful consideration, we feel that your manuscript will likely be suitable for publication if it is revised to address a specific topic raised by the reviewers. According to reviewer, there are some specific areas where further improvements would be of substantial benefit to the readers, including methods and results.   For your guidance, a copy of the reviewers' comments was included below. 

Please submit your revised manuscript by November 20. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols

We look forward to receiving your revised manuscript.

Kind regards,

Luzia Helena Carvalho, Ph.D.

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Please state whether the baseline demographic characteristics of the study populations were recorded. If so, please provide a table summarising these.

3. PLOS requires an ORCID iD for the corresponding author in Editorial Manager on papers submitted after December 6th, 2016. Please ensure that you have an ORCID iD and that it is validated in Editorial Manager. To do this, go to ‘Update my Information’ (in the upper left-hand corner of the main menu), and click on the Fetch/Validate link next to the ORCID field. This will take you to the ORCID site and allow you to create a new iD or authenticate a pre-existing iD in Editorial Manager. Please see the following video for instructions on linking an ORCID iD to your Editorial Manager account: https://www.youtube.com/watch?v=_xcclfuvtxQ

4. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: The authors update the epidemiological situation in Kuwait, which basically depends on imported malaria, and shows that Kuwait has adequate policies and a health system that is currently preventing the emergence of autochthonous cases. The high proportion of mixed malaria P. vivax + P. falciparum is noteworthy, which the affected people acquired in their countries of origin, mainly India and which are not detected because they do not routinely use diagnostic methods with limited sensitivity. The significance of this finding is that mixed infection is much more frequent than is diagnosed in the countries of origin and the need in the near future to use radical university treatment for both species.

It would be convenient for the authors to specify the treatment scheme used in Kuwait, they mention the use of chloroquine plus primaquine (there is no dose information) for 28 days, however they observe 20% relapses. Assuming that in Kuwait the dose of primaquine (PQ) that they use is the one recommended by WHO (0.25 mg / kg), the total dose per kilo would be at high dose levels of PQ (7 mg / kg) where the frequency of relapses is very low (~ 1%). However, it is also published in mixed malaria, an increase in relapses by vivax after treatment of P. falciparum. It would justify the authors to make a comment on adherence to treatment in the 28-day period. I also suggest that the authors make some comment on the possibility of future use of tafenoquine due to the high relapse rate, Kuwait being a country where the economic factor is not a limitation.

Reviewer #2: Thank you very much for giving me the opportunity to review the manuscript “PONE-D-20-30612” titled as “Decreasing trend of imported malaria cases but increasing influx of mixed P. falciparum and P. vivax infections in malaria-free Kuwait”. The authors sought to characterize the incidence of imported malaria infection and evaluated the impact of malaria preventive measures in Kuwait using a retrospective chart review over a 6-year period. The authors note a total of 1913 (25.9%) malaria cases, 81.5% of which were among male subjects. Also, majority of malaria cases (1895; 99.1%) were detected among expatriates from 38 malaria-endemic countries. Overall, the paper is nicely written. However, there are spaces for improvement. I have few comments:

Methods:

• What prevention and control measures were in place?

• Data collection paragraph does not detail the procedure for data abstraction. There is need to describe how the facility collected malaria information. Who collected the samples? All these relevant information should be clearly indicated in the “Methods and materials" section.

• How was consistency assessed? It is important to include data with a few missing variables to avoid bias, please clarify how many records were excluded due to incomplete data.

• How malaria positive patients were administered?

Discussion:

• Reference for lines 252-253

• Please re-read for grammar edits pp. 12, line 255 insert comma (,) after “On the contrary,…”

Thank you very much.

Araya Gebresilassie (Ph.D)

Department of Zoological Sciences, Addis Ababa University

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Alejandro Llanos-Cuentas MD, PhD

Reviewer #2: Yes: Araya Gebresilassie

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Attachment

Submitted filename: Reviewers comment on PONE-D-20-30612.docx

PLoS One. 2020 Dec 11;15(12):e0243617. doi: 10.1371/journal.pone.0243617.r002

Author response to Decision Letter 0


5 Nov 2020

Dated: 5th November, 2020

Dear Ms Carvalho

Academic Editor, PLOS ONE

Re: PONE-D-20-30612

‘Decreasing trend of imported malaria in cases but increasing influx of mixed P. falciparum and P. vivax infections in malaria-free Kuwait’.

With reference to above manuscript, I take this opportunity to thank you and both the reviewers, Prof. Llanos-Cuentas and Prof. Gebresilassie on their thorough review and excellent suggestions to further improve the quality of the manuscript.

We have made the appropriate changes and edits as suggested by the Reviewers. The itemized responses to their queries are follows:

Both the reviewers have agreed and have no suggestion/comments to the following questions:

1. Is the manuscript technically sound, and do the data support the conclusions?

2. Has the statistical analysis been performed appropriately and rigorously?

3. Have the authors made all data underlying the findings in their manuscript fully available?

4. Is the manuscript presented in an intelligible fashion and written in standard English?

Review Comments to the Author

Reviewer 1:

Query 1 & 2: Specify the malaria treatment scheme used in Kuwait & comment on 28-day treatment with primaquine

Answer: We have edited the text as follows on Page 13, lines 259-270 and included two additional references (#35, 36).

All mixed infections with P. falciparum + P. vivax were treated with artemether+lumefantrine, given twice a day for 3 days. This treatment was followed by treatment with the standard dose of primaquine (0.25 mg/kg/day) for 28 days to treat hypnozoite stage of the P. vivax. Though the WHO has also recommended a higher dosage of primaquine (0.5 mg/kg/day) for 14 days, however, we used the standard dose for primaquine to minimize the side effect of hemolysis especially in patients with glucose‐6‐phosphate dehydrogenase (G6PD) deficiency. However, up to 20% of the mixed Plasmodium cases showed relapse of mixed Plasmodium infection 3-4 months after therapeutic/radical anti-malarial treatment with no travel history to the Indian sub-continent. A number of studies have reported in mixed malaria, an increase in relapse rates by P. vivax following treatment of P. falciparum [35]. Though, the most common cause of P. vivax relapse is poor adherence to treatment or inappropriate dose, however, failure in treatment due to impairment in CYP2D6 enzyme is also being investigated [36].

Query #2: make some comment on the possibility of future use of tafenoquine

Answer: Though the use of Tafenoquine as a single-dose (300 mg) therapy for P. vivax relapse prevention was discussed but not yet approved by the Ministry of Health, Kuwait, considering its safety challenge in causing severe hemolytic anemia in people with G6PD deficiency. However, we hope that the Ministry of Health may approve its use soon considering rise of P. vivax relapses following treatment of mixed malaria infections.

Reviewer 2:

Query 1 & 2: What prevention and controlmeasures were in place & What was the detail on Data collection?

Answer: We have edited the text as follows on Page 4, lines 74-86 under Materials & Methods.

Malaria infection is a notifiable disease in Kuwait. Though all migrant workers from malaria endemic countries entering Kuwait for the 1st time are required to carry a recent malaria-free certification issued by the designated Diagnostic Laboratories in their home countries, however, they are also screened for malaria infection at the Ports and Borders Health Centers in Kuwait. Kuwait is a small country consisting of six administrative governorates. All malaria positive cases are then referred to the Malaria Reference Laboratory, Infectious Diseases Hospital (MRL, IDH), Kuwait for treatment and follow up. In addition, any resident in Kuwait suspected of malaria infection is referred to the MLR, IDH for confirmation and therapeutic management. For all cases, information on civil identification number, age, gender, nationality, referring hospital, date of sample collection, major clinical symptoms, recent travel history and test results are recorded in the MLR, IDH registry logbooks. The epidemiologic and demographic data of all cases was collected from the registry logbooks of MRL, IDH during the period January 2013 to December 2018.

Query 3: How was consistency assessed?

Answer: As mentioned above, the epidemiological data for all referred cases was recorded in the MLR, IDH registry logbooks. There were just 4-5 cases with missing information on their nationality and/or travel history, which we did not include in our data as the number was very small.

Query 4: How malaria positive patients were administered?

Answer: Please refer to our answer to query # 1 & 2 for the 1st reviewer, and is the edited text is added at Page 13, lines 259-270

Query 5: Reference for lines 252-253

Answer: The reference # 19 & 23 is included, as suggested.

Query 6: Please re-read for grammar edits pp. 12, line 255 insert comma (,) after “On the contrary,…”

Answer: The sentence is edited, as suggested.

I hereby, certify that all the authors have reviewed and agreed to the revised version and answers to reviewer’s queries. We hope that the revised version of the manuscript will be acceptable for publication to the Journal PLOS ONE.

Regards

Dr. Jamshaid Iqbal

Corresponding Author

Attachment

Submitted filename: Responses to Reviewers.docx

Decision Letter 1

Luzia Helena Carvalho

25 Nov 2020

Decreasing trend of imported malaria cases but increasing influx of mixed P. falciparum and P. vivax infections in malaria-free Kuwait

PONE-D-20-30612R1

Dear Dr. iqbal,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Luzia Helena Carvalho, Ph.D.

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

Reviewer #2: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: The authors have incorporated the reviewers' suggestions, both regarding the potential use of tafenoquine as adherence to treatment. Kuwiat being a country with basically imported malaria to date, its health system has proven to be efficient in preventing malaria from being endemic in this country.

The discussion as well as the abstract of the paper has been improved. I agree with the changes made. I have no further suggestions.

Reviewer #2: (No Response)

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: Yes: Dr. Araya Gebresilassie

Acceptance letter

Luzia Helena Carvalho

1 Dec 2020

PONE-D-20-30612R1

Decreasing trend of imported malaria cases but increasing influx of mixed P. falciparum and P. vivax infections in malaria-free Kuwait

Dear Dr. Iqbal:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Luzia Helena Carvalho

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 File

    (DOCX)

    Attachment

    Submitted filename: Reviewers comment on PONE-D-20-30612.docx

    Attachment

    Submitted filename: Responses to Reviewers.docx

    Data Availability Statement

    All relevant data are within the manuscript and its Supporting information files.


    Articles from PLoS ONE are provided here courtesy of PLOS

    RESOURCES